Cinacalcet Tablet, Film Coated
Product Images NDC 60687-516

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Cinacalcet (NDC 60687-516). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 mg Cinacalcet Tablet Blister.jpg (30 mg Cinacalcet Tablet Blister)

Multiple identical labels for Cinacalcet 30 mg film-coated tablets. Each label includes the product name, dosage strength, dosage form, a barcode with the NDC 60687-516, spaces for expiration date and lot number, and the labeler American Health Packaging, Columbus, Ohio.*

FDA Label Image

30 mg Cinacalcet Tablets Carton.jpg (30 mg Cinacalcet Tablets Carton)

Label for Cinacalcet 30 mg film-coated tablets from American Health Packaging. The label shows the product name, dosage form (tablets), strength (30 mg), and package size of 30 tablets (3 blister packs of 10). It includes storage instructions, usage notes, and features a barcode and QR code for prescribing information. It is marked Rx Only.*

FDA Label Image

Cinacalcet-structure (61399d7c Ee88 4df1 B3b3 B4995e787a53 01)

Chemical structure of Cinacalcet hydrochloride shown as a molecular diagram, highlighting its specific atomic and bond arrangement with a trifluoromethyl group, aromatic rings, and a hydrochloride component.*

FDA Label Image

Figure 1 (61399d7c Ee88 4df1 B3b3 B4995e787a53 02)

A line graph showing serum iPTH (pg/mL) levels over 26 weeks comparing Cinacalcet with placebo. The x-axis represents weeks, and the y-axis shows iPTH levels with values from 0 to 1000 pg/mL. Cinacalcet is depicted by a red line showing a decreasing trend, while placebo is shown by a black dashed line with relatively stable levels.*

FDA Label Image

Figure 2 (61399d7c Ee88 4df1 B3b3 B4995e787a53 03)

A line graph comparing Ca x P (mg/dL) levels over 26 weeks between a Cinacalcet treatment group and a placebo group. The x-axis shows time in weeks, and the y-axis shows Ca x P levels. Cinacalcet data is represented by a red line with error bars showing levels decreasing and stabilizing lower than those in the placebo group, which is depicted by a black dashed line with error bars.*

FDA Label Image

Figure-3 (61399d7c Ee88 4df1 B3b3 B4995e787a53 04)

A line graph showing calcium levels (mg/dL) over time in weeks for patients with parathyroid carcinoma. The x-axis represents weeks, divided into titration and maintenance phases, while the y-axis shows calcium concentration ranging from 8 to 16 mg/dL. Data points include error bars and sample sizes are indicated for each time point.*

FDA Label Image

Figure-4 (61399d7c Ee88 4df1 B3b3 B4995e787a53 05)

A line graph showing calcium levels (mg/dL) over time in weeks during the titration and maintenance phases of treatment. Calcium levels initially decrease sharply during titration and then stabilize, with minor fluctuations during maintenance. The graph includes error bars for each data point and reports the number of subjects (n) for each time point below the x-axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.